{"id":5887,"date":"2024-02-29T11:00:19","date_gmt":"2024-02-29T02:00:19","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=5887"},"modified":"2024-03-04T10:58:38","modified_gmt":"2024-03-04T01:58:38","slug":"202040229","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2024\/02\/29\/202040229\/","title":{"rendered":"Preliminary Cancer Detection Rates After Use of N-NOSE Dogs Released"},"content":{"rendered":"

HIROTSU Bioscience Inc. (Head Office:\nChiyoda-ku, Tokyo, Representative: Takaaki Hirotsu, hereinafter referred to as \u201cHIROTSU)\nhas verified the cancer detection rate*1<\/sup> from the claim data after\nthe use of \u201cN-NOSE Dogs\u201d based on the insurance claim information of Anicom\nInsurance Inc. (Head Office: Shinjuku-ku, Tokyo, Representative : Shingo Noda,\n, hereinafter referred to as \u201cAnicom\u201d).<\/strong><\/p>\n\n\n\n

Cancer is the leading cause of death in\ndogs. The number of deaths per age group is rising sharply, especially after\nthe age of 5~6 years, and it is known that 21% of all deaths at the age of 10\nyears are due to cancer. *2<\/sup> Therefore, as in the case of humans,\nearly detection of cancer in dogs is considered to be important.<\/p>\n\n\n\n

In order to ensure that our service “N-NOSE\nDogs”, which is linked to early detection of cancer in dogs, can be used\nby all, we have conducted a survey on tumor claims after the use of “N-NOSE\nDogs”. The survey was conducted on 883 cases among Anicom’s pet insurance policyholders\nwho used the “N-NOSE Dogs” service and were sent the results between\nmid-June and mid-September 2023, to determine whether they received tumor\ntreatment. The results of this survey are calculated based on the information\non claims submitted to Anicom Insurance after medical treatment related to the tumor.<\/p>\n\n\n\n

\u25a0Survey\nReport<\/p>\n\n\n\n

– Of the 883 canine subjects*3 who underwent the “N-NOSE Dogs” test, 22 cases (2.5%) underwent tumor treatment and submitted insurance claims.
– 1.2% for low risk (A, B), 3.6% for medium risk (C) and 6.3% for high risk (D, E)
– As for each risk assessment, the tumor detection rate for Result A was 1.1%, whereas the tumor detection rate for Result E was 14.9%, approximately 13.5 times higher.<\/p>\n\n\n\n

\u25a0Survey Summary
\u25b6Targets
\u201cN-NOSE Dogs\u201d\u00a0 users which decision results (A to E) were disclosed between mid-June and mid-September 2023*4<\/sup>
\u25b6Number of cases
883 cases
\u25b6Method
Data aggregation based on insurance claim details.
\u25b6Items
1. Tumor detection rate by judgment group (low, medium, and high risk)
2. Tumor detection rate for each judgment*5<\/sup> (A, B, C, D, E)<\/p>\n\n\n\n

\u25a0Survey Results
1. Tumor detection rate by decision group (low, medium, and high risk)<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The tumor\ndetection rate in the low-risk group (A, B) was 1.2%, in the medium-risk group\n(C) 3.6%, and in the high-risk group (D, E) 6.3%, Thus, the\ntumor detection rate in the high-risk group was 5.2 times higher than that in\nthe low-risk group..<\/p>\n\n\n\n

2. Tumor detection rate by each classification <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The tumor detection rate for the E  was approximately 13.5 times higher compared\nto the A.<\/p>\n\n\n\n

*1 Percentage of the number of dogs for which claims were made that fit the following criteria.
\u30fbMust have a claim for surgery for a tumor.
\u30fbContinuous claims with tumor at least 5 times.
*2 Anicom White Paper on Household Animals 2023 Causes of death in dogs at age 10
*3 Only test results linked to contract information
*4 Includes continuing treatment from prior to disclosure of test results and treatment of suspected recurrence with previous treatment.
*5 “N-NOSE Dogs” results are determined on a 5-point scale from A, B, C, D, and E, in descending order of risk from lowest to highest.<\/p>\n\n\n\n

Download PDF<\/a><\/a><\/div>","protected":false},"excerpt":{"rendered":"

HIROTSU Bioscience Inc. (Head Office: Chiyoda-ku, Tokyo, Representative: Takaaki Hirotsu, hereinafter referred […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"5887","footnotes":""},"categories":[3],"tags":[],"class_list":["post-5887","post","type-post","status-publish","format-standard","hentry","category-press-release","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/5887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=5887"}],"version-history":[{"count":1,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/5887\/revisions"}],"predecessor-version":[{"id":5891,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/5887\/revisions\/5891"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=5887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=5887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=5887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}